Physician profile
Danielle Manolakos
NPI 1760651921
$13,166.13
in general payments reported to CMS, 2019-2025
22 companies · $9,062 in 2025
The $9,062 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $150 · 2021: $306 · 2022: $574 · 2023: $1,250 · 2024: $1,011 · 2025: $9,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500 · Food and Beverage: $3,509 · Travel and Lodging: $1,039 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
| Food and Beverage | $3,508.51 |
| Travel and Lodging | $1,038.94 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $8,437.33 | 2020-2025 | Odomzo, Blu-U, Ilumya |
| Janssen Biotech, INC. | $790.36 | 2019-2025 | Tremfya |
| Merz North America, INC. | $657.83 | 2019-2025 | Xeomin |
| Abbvie INC. | $621.77 | 2023-2025 | |
| Galderma Laboratories, L.P. | $322.69 | 2019-2025 | |
| Genzyme Corporation | $288.04 | 2019-2025 | |
| Incyte Corporation | $258.80 | 2021-2025 | Opzelura |
| Pfizer INC. | $250.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $231.21 | 2024-2025 | Dupixent |
| Leo Pharma INC. | $194.81 | 2019-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $188.06 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $186.51 | 2019-2024 | |
| Amgen INC. | $180.06 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $126.99 | 2023-2025 | Zoryve |
| Almirall LLC | $108.60 | 2019-2025 | Klisyri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $82.09 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.84 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Mayne Pharma Commercial LLC | $51.68 | 2019 | |
| Allergan, INC. | $48.54 | 2022 | |
| Celgene Corporation | $40.88 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.89 | 2025 | Ycanth |
| Pierre Fabre Pharmaceuticals, INC. | $16.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Manolakos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.